Weiss Lawrence T 4

What Happened
Lawrence T. Weiss, Senior Vice President and Chief Legal Officer of AngioDynamics, received equity awards on July 15, 2026: 21,288 restricted stock units (RSUs) and 21,288 performance rights. Both awards were granted at $0 per share (standard for equity awards) and reported on a Form 4 filed July 22, 2026. These are grants (not open-market purchases or sales) and represent compensation rather than a cash transaction.

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 22, 2026 (appears outside the typical 2-business-day filing window).
• Award types and amounts: 21,288 RSUs and 21,288 performance rights (both reported as acquisitions, code “A”). Grant price reported $0.
• Vesting for RSUs (F1): RSUs vest in four equal annual installments beginning July 15, 2027 (25% vests each July 15 in 2027, 2028, 2029, 2030).
• Performance rights (F2): Each right converts to one share if earned. Payout ranges from 0%–200% of target based on total shareholder return (TSR) vs. peers over a three-year period, with a possible ±20% adjustment on the calculated achievement — for a total potential payout up to 240% of target (i.e., up to roughly 51,091 shares at maximum). Any unearned performance rights are forfeited.
• Shares owned after transaction: not specified in the provided excerpt.
• Filing timeliness: filing date is July 22 for a July 15 grant — this appears late relative to the usual 2-business-day Form 4 deadline.

Context
These awards are part of executive compensation and common practice to align management incentives with shareholder performance. RSUs provide time-based retention, while the performance rights tie payout to relative TSR over a multi-year period; neither represents an immediate cash investment or sale by the insider.